94 related articles for article (PubMed ID: 6187785)
1. Inhibition of 3',5'-cyclic nucleotide 3'-phosphohydrolase by a novel 1',2'-cyclic nucleotide.
Nair V; Wiechert RJ; Young DA
J Cyclic Nucleotide Res; 1982; 8(3):181-90. PubMed ID: 6187785
[No Abstract] [Full Text] [Related]
2. Inhibition of cyclic AMP phosphodiesterases by cyclic nucleotide analogs and nitrogen heterocycles.
Miller JP; Sigman CC; Johnson HL; Novinson T; Springer RH; Senga K; O'Brien DE; Robins RK
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():277-90. PubMed ID: 6326528
[No Abstract] [Full Text] [Related]
3. Trapidil derivatives as potent inhibitors of cyclic AMP phosphodiesterase from heart and coronary arteries.
Bartel S; Tenor H; Krause EG
Biomed Biochim Acta; 1985; 44(5):K31-5. PubMed ID: 2415118
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclic AMP phosphodiesterase by 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)] ethyl ester 5-methyl ester hydrochloride (YC-93), a potent vasodilator.
Sakamoto N; Terai M; Takenaka T; Maeno H
Biochem Pharmacol; 1978; 27(8):1269-74. PubMed ID: 81059
[No Abstract] [Full Text] [Related]
5. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
[No Abstract] [Full Text] [Related]
6. Griseolic acid, a cAMP phosphodiesterase inhibitor, and its ester: increase in cellular cAMP levels and reduction of intraocular pressure.
Yamazaki M; Yasumoto T; Iijima Y; Yokoyama T; Fukami S; Kaneko M; Kiuchi Y; Mishima H
Adv Second Messenger Phosphoprotein Res; 1990; 24():502-6. PubMed ID: 1698412
[No Abstract] [Full Text] [Related]
7. [Inhibition of cyclic nucleotide phosphodiesterase from rabbit heart by hydroxypyridines].
Polyansky NB; Smirnov LD; Shvedova AA; Kagan VE; Tkachuk VA
Vopr Med Khim; 1983; 29(1):123-7. PubMed ID: 6301154
[TBL] [Abstract][Full Text] [Related]
8. Cyclic AMP phosphodiesterase inhibition by coumarins and furanocoumarins.
Sardari S; Nishibe S; Horita K; Nikaido T; Daneshtalab M
Pharmazie; 1999 Jul; 54(7):554-6. PubMed ID: 10445247
[No Abstract] [Full Text] [Related]
9. Inhibition of cyclic AMP phosphodiesterase activity and myocardial contractility: effects of cilostamide, a novel PDE inhibitor, and methylsiobutylxanthine on rabbit and canine ventricular muscle.
Endoh M; Satoh K; Yamashita S
Eur J Pharmacol; 1980 Aug; 66(1):43-52. PubMed ID: 6157546
[No Abstract] [Full Text] [Related]
10. A new nonhydrolyzable reactive cAMP analog, (Sp)-adenosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase.
Hung SH; Madhusoodanan KS; Beres JA; Boyd RL; Baldwin JL; Zhang W; Colman RW; Colman RF
Bioorg Chem; 2002 Feb; 30(1):16-31. PubMed ID: 11955000
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of platelet aggregation and cyclic nucleotide phosphodiesterase (specifically cyclAMP) by 3-hydroxypyridine derivatives].
Kagan VE; Polianskiĭ NB; Muranov KO; Shvedova AA; Smirnov LD
Biull Eksp Biol Med; 1984 Apr; 97(4):416-8. PubMed ID: 6202339
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of NZ-105, a 1,4-dihydropyridine derivative, on cyclic nucleotide phosphodiesterase activity.
Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y
J Pharm Pharmacol; 1993 Jun; 45(6):530-4. PubMed ID: 7689649
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
Ilien B; Ruckstuhl M; Landry Y
J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
[TBL] [Abstract][Full Text] [Related]
14. Silymarin: potent inhibitor of cyclic AMP phosphodiesterase.
Koch HP; Bachner J; Löffler E
Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):409-13. PubMed ID: 3001454
[TBL] [Abstract][Full Text] [Related]
15. [The relationship between the intracellular content of 1-methyl-3-isobutylxanthine and the permeability for water of the bladder wall in the frog].
Natochin IuV; Parnova RG; Firsov DL; Shakhmatova EI; Kaminskiĭ IuL
Fiziol Zh SSSR Im I M Sechenova; 1989 Dec; 75(12):1766-71. PubMed ID: 2483381
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of fibroblast cyclic AMP escape and cyclic nucleotide phosphodiesterase activities by xanthines.
Nemecek GM; Wells JN; Butcher RW
Mol Pharmacol; 1980 Jul; 18(1):57-64. PubMed ID: 6251359
[No Abstract] [Full Text] [Related]
17. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
Medvedeva MV
Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of cyclic AMP phosphodiesterase by cortisol.
Schmidtke J; Wienker T; Flügel M; Engel W
Nature; 1976 Aug; 262(5569):593-4. PubMed ID: 183135
[No Abstract] [Full Text] [Related]
20. Negative regulation of cyclic AMP levels by activation of cyclic nucleotide phosphodiesterases: the example of the dog thyroid.
Dumont JE; Miot F; Erneux C; Couchie D; Cochaux P; Gervy-Decoster C; Van Sande J; Wells JN
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():325-36. PubMed ID: 6202125
[No Abstract] [Full Text] [Related]
[Next] [New Search]
